secwatch.observer — SEC 8-K summary
======================================

Issuer:     SURGALIGN HOLDINGS, INC. (—)
CIK:        0001760173
Form:       8-K/A
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-061153
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surgalign updates restructuring: targets $30-35M savings, reports ~$82M revenue, sells Coflex/CoFix for $17M
--------------------------------------------------------------------------------

- Inventory write-down of $12.5-15.5M in Q4 2022 due to product rationalization.
- Workforce reduced by ~20% in December 2022; target cash savings of $30-35M in 2023 vs 2022.
- Preliminary 2022 revenue ~$82M; year-end cash ~$16.3M.
- Closed sale of Coflex/CoFix brands to Xtant Medical for $17M on March 1, 2023.
- Product rationalization expected by mid-2023; ~70% of 2022 revenue from ~30% of brands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760173/000119312523061153/0001193125-23-061153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760173/000119312523061153/d444936d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-061153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer